NK cells are critical for the control of viral infections. Studies have shown that efficient NK cell activation in response to infection with VV in vivo requires multiple pathways, including the NKG2D pathway. We have recently shown that IL-18 is necessary for the activation of NK cells through upregulation of the NKG2D ligand Rae-1 on DCs upon VV infection. However, how IL-18R signaling on the accessory cells contributes to Rae-1 up-regulation remains to be defined. In this study, we found IL-18-mediated Rae-1 up-regulation in accessory cells, including macrophages and DCs, to be dependent on the MyD88-PI3K pathway. We further found that IL-18 signaling through PI3K led to inhibition of GSK-3, which we found to be a negative regulator of Rae-1. Finally, we demonstrated that in vivo inhibition of GSK-3 could restore Rae-1 up-regulation on IL18R 2/2 DCs and partially rescue NK-cell activation against VV, leading to improved viral control in IL-18R 2/2 mice. Our results showed that IL18-dependent Rae-1 up-regulation on accessory cells is mediated by the MyD88-PI3K-GSK3 pathway. These observations may provide important insights into the design of effective NK cell-based immunotherapies.
Introduction
NK cells are important for the control of viral infections [1] [2] [3] . Studies have shown that NK cells are essential for the control of poxviruses, including VV [4] [5] [6] [7] . In a model of VV infection, we have shown that efficient activation of NK cells and subsequent control of VV infection in vivo requires multiple pathways, including that of the NKG2D activating receptor, which recognizes host stress-induced NKG2D ligands [6] [7] [8] .
The NKG2D activation receptor plays an important role in antiviral immunity and tumor immune surveillance [9] . Inhibition of NKG2D signaling through genetic deletion or blocking Ab treatment can result in higher viral loads or larger tumors [7, 10, 11] . Conversely, forced expression of NKG2D ligands on tumor cells can make otherwise refractory tumors sensitive to NK cellmediated killing [12] . Accessory cells including DCs and macrophages are critical for NK cell activation by expressing ligands to the NKG2D receptor [13] . We have recently shown that IL-18 signaling on DCs can up-regulate Rae-1 to promote efficient NK cell activation in response to VV infection [14] . However, the mechanism by which IL-18R signaling on accessory cells contributes to Rae-1 up-regulation remains unknown.
In this study, we first showed that, similar to our observation in DCs, rIL-18 was sufficient to up-regulate the expression of Rae-1 on macrophages and that that IL-18-mediated Rae-1 up-regulation was dependent on the MyD88 adaptor. Using chemical inhibitors to cell-signaling molecules downstream of MyD88, we found that Rae-1 up-regulation in response to IL-18 was mediated through the PI3K pathway. We further revealed that IL-18 signaling through PI3K could inhibit GSK-3, which we found to be a negative regulator of Rae-1. Finally, we demonstrated that in vivo inhibition of GSK-3 could restore Rae-1 up-regulation on IL18R 2/2 DCs and partially rescue NK-cell activation against VV, leading to a better viral control in IL-18R 2/2 mice. Our results reveal that IL-18R-MyD88 signaling can control Rae-1 up-regulation via PI3K-mediated suppression of GSK-3, a negative regulator of Rae-1.
MATERIALS AND METHODS

Mice
C57BL/6 mice were obtained from the Frederick National Laboratory for Cancer Research at the National Cancer Institute (Frederick, MD, USA). IL-18R 2/2 mice (deficient in IL-18Ra) [15] on the C57BL/6 background were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). MyD88
mice on the C57BL/6 background were kindly provided by Shizuo Akira To assess intracellular production of IFN-g, splenocytes were incubated with 25 ng/ml PMA, 25 ng/ml ionomycin, and 5 mg/ml Brefeldin A, containing Golgi-Plug (BD Biosciences) for 4 h at 37°C. These low doses increase the sensitivity of the assay without activating naive NK cells [14] . To assess intracellular production of GRB, splenocytes were cultured with 5 mg/ml Brefeldin A containing Golgi-Plug alone for 4 h at 37°C. After incubation, cells were stained for surface molecules, permeablized with the Cytofix/Cytoperm kit according to the manufacturer's instructions and stained for intracellular molecules. FACS Canto (BD Biosciences) was used for flow cytometry event collection, which was analyzed with FlowJo software 9.5.3 (Tree Star, Ashland, OR, USA).
Macrophage culture
To attain macrophages for in vitro culture, peritoneal macrophages were harvested by peritoneal lavage with 5 ml cold PBS with a 5 ml syringe. Two to 3 days before harvesting, mice were injected intraperitoneally with 1.5 ml 3% fluid thioglycollate medium (BD Biosciences) to elicit mild peritonitis and recruit macrophages into the peritoneum. All cultures of macrophages were performed in 96-well U-bottom plates. Recombinant mouse IL-18 protein (Thermo Fisher Scientific) was used at 5 ng/ml. Chemical inhibitors of cell signaling molecules were incubated with macrophages for 1 h before the addition of agonist. The PI3K inhibitor Ly294002 (EMD Millipore, Billerica, MA, USA) and the GSK-3 inhibitor SB216763 (Sigma-Aldrich, St. Louis, MO, USA) were both used at 10 mM.
DC culture
DC cultures were performed as described [7] . In brief, DCs were generated from bone marrow cells after 4 days of culture with GM-CSF (1000 U/ml) and IL-4 (500 U/ml) (R&D Systems, Minneapolis, MN, USA). On day 2, nonadherent cells were removed and fresh medium was added.
Quantitative real-time PCR
Total RNA was extracted from CD11c + DCs with TRIzol solution (Thermo Fisher Scientific). Reverse transcription was performed with the ImProm-II reverse-transcription system (Promega, Madison, WI, USA) and random primers. Oligonucleotide primers were as follows: Rae-1 (forward: 59-CTATGGATACACCAACGGGCT-39; reverse: 59-ACTTCGCTTCATACC-AGAGAGG-39); and actin (forward: 59-AGCCATGTACGTAGCCATCC-39; Reverse: 59-CTCTCAGCTGTGGT GGTGAA-39). Quantitative PCR was performed with the MyiQ iCycler system (Bio-Rad) and the iQ SYBR Green PCR mastermix (Bio-Rad). All experiments were performed 3 separate times in duplicate. Amounts of mRNA were normalized to b-actin mRNA levels within each sample.
Vaccinia virus
The Western Reserve (WR) strain of VV was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). VV was grown in TK-143B cells (ATCC) and purified by a 35% sucrose cushion [8] . The titer was determined by plaque assay on TK-143B cells, and VV was stored at 280°C until use. For in vitro studies, VV was used at a multiplicity of infection of 1. For in vivo studies, 5 3 10 6 pfu of live VV in 0.05 ml of 1 mM Tris (pH 9.0) was injected intraperitoneally.
Measurement of viral load
Viral load in the ovaries was measured by plaque-forming assay [6] . Two days after infection with 5 3 10 6 pfu VV, ovaries were harvested into 10 mM Tris (pH 9.0) and stored at 280°C until use. The viral load was then measured by plaqueforming assay. Ovaries were first homogenized and freeze thawed 3 times. Serial dilutions of the lysate were added to confluent TK-143B cells, and the number of plaques was counted by using crystal violet staining after 2 days of culture at 37°C.
In vivo GSK-3 inhibition
The GSK-3 inhibitor SB216763 (Sigma-Aldrich) was diluted in PBS with 1% FBS and injected intraperitoneally into mice 1 d and 1 h before infection with VV. It was used at the dose of 2.5 mg/kg. Control mice received vehicle (PBS with 1% FBS). Mice were harvested for splenic analysis by flow cytometry 1 d after infection.
Statistical analysis
All data are presented as means and SE. All indicated statistical tests, including unpaired Student's t test, ANOVA, and ANCOVA, were performed with GraphPad Prism 6 software (GraphPad Software, La Jolla, CA, USA).
Significance was assumed at P , 0.05.
RESULTS
IL-18 promotes the expression of Rae-1 on macrophages via MyD88
We have demonstrated that IL-18 up-regulates Rae-1 expression on DCs in response to VV infection [14] . However, it remained unknown whether rIL-18 is capable of up-regulating the expression of Rae-1 on macrophages. To test this, peritoneal macrophages were cultured with or without rIL-18, and the RNA and surface protein expression of Rae-1 was analyzed every 12 h by real-time PCR and FACS analyses. We found that IL-18 could begin to enhance Rae-1 mRNA ( Fig. 1A) and protein ( Fig. 1B , C) expression as soon as 24 h after the beginning of culture, achieving peak effect at 48 h (P , 0.0001). We further showed that no Rae-1 up-regulation was observed on IL-18R 2/2 macrophages ( Fig. 1D-F ), confirming the specificity of this effect. Mild up-regulation in Rae-1 expression was observed in untreated macrophages at 48 h. The reason for this up-regulation is not entirely clear, but it could be related to increased cellular stress in the culture condition over time. This up-regulation was not dependent on IL-18R signaling (Fig. 1E, F) . We did not notice up-regulation of other NKG2D ligands such as Mult-1 and H60 (data not shown).
We next sought to investigate whether IL18-dependent Rae-1 up-regulation is mediated by the common adaptor MyD88. To address this question, we cultured WT and MyD88 2/2 macrophages with rIL-18 for 48 h and assayed for Rae-1 mRNA and surface protein expression. We found that, although WT macrophages robustly up-regulated Rae-1 expression in response to IL-18 (P , 0.0001), MyD88 2/2 macrophages failed to up-regulate Rae-1 expression at the RNA ( Fig. 2A) 
IL-18 signals through PI3K to up-regulate Rae-1 expression
To investigate the mechanism underlying IL-18-mediated Rae-1 up-regulation, we examined cell-signaling molecules downstream of MyD88. IL-18R-MyD88 signaling has been shown to trigger the recruitment of TIR domain-containing IRAK4, leading to the activation of NF-kB, p38, and JNK that promote the transcription of a panel of proinflammatory genes [16] . However, MyD88 has also been shown to physically interact with PI3K through a SH2 binding motif within its TIR domain. This association can be used to signal through Akt and influence cytokine production and other effector functions in a variety of different leukocytes [7, 17, 18] . The MyD88-PI3K signaling pathway proved particularly interesting, as others have associated PI3K with Rae-1 expression in the context of MCMV infection and cancer [19] . To test whether MyD88 signals through PI3K to influence Rae-1 up-regulation, we pretreated macrophages with an inhibitor of PI3K (Ly294002) for 1 h before culturing them with IL-18. After 48 h, we analyzed expression of Rae-1 on the macrophages (Fig. 3A-C) and found that inhibition of PI3K abrogated IL-18-mediated Rae-1 up-regulation (P , 0.0001). This result suggests that MyD88 signaling through PI3K is necessary for Rae-1 up-regulation in macrophages.
Much of our work in this study, as well as work by others [20] , has shown NKG2D ligand up-regulation in response to MyD88 stimulation in macrophages, but DCs have a better defined in vivo role as accessory cells in NK-cell activation [21] . In particular, we have shown the importance of IL-18 signaling in the control of NKG2D ligands on DCs in NK-cell activation to VV infection [14] . Therefore, we asked whether PI3K signaling is also necessary for IL-18-mediated Rae-1 up-regulation on DCs as well. We cultured bone marrow-derived DCs for 4 d in the absence or presence of rIL-18 and the PI3K inhibitor Ly294002, and found that IL-18-mediated up-regulation of Rae-1 expression was abrogated upon inhibition of PI3K signaling in DCs (P , 0.0001; Fig. 3D, E) . Collectively, we can conclude that PI3K is important for MyD88 signaling in the control of Rae-1 expression in both macrophages and DCs.
IL18R-MyD88-PI3K signaling inhibits GSK-3, a negative regulator of Rae-1 expression
We next sought to understand how MyD88 signaling to PI3K could influence Rae-1 expression. GSK-3, acting downstream of PI3K, is a pleiotropic kinase originally described in insulin signaling and glycogen metabolism [22] [23] [24] . It serves as a negative regulator to control many events, including cytokine production [25] . PI3K signaling through Akt has been shown to result in phosphorylation of GSK-3 at Ser 9 and inhibition of its function in macrophages [25] . We therefore hypothesized that the same MyD88-PI3K signaling pathway could inhibit GSK-3 to release its putative breaks on the expression of Rae-1. Because PI3K-mediated phosphorylation of GSK-3 at the Ser 9 position has been shown to abrogate GSK-3 function [25] , we first sought to examine whether IL-18-PI3K signaling promotes the inhibitory phosphorylation of GSK-3. Indeed, we found that IL-18 treatment in macrophages led to an increase in the inhibitory phosphorylation of GSK-3 (Fig. 4A, B) . This increase can also be blocked by the addition of the PI3K inhibitor Ly2940002. These data suggest that IL-18 promotes the generation of phosphorylated GSK-3 through PI3K.
Next, we tested whether GSK-3 is a negative regulator of Rae-1 expression. Our hypothesis predicted that inhibition of GSK-3 alone should be sufficient to up-regulate Rae-1 expression. We therefore treated WT and MyD88 2/2 macrophages with a specific inhibitor to GSK-3 (SB216763) and analyzed its effect on Rae-1 expression. We observed an up-regulation of Rae-1 expression on WT and MyD88 2/2 macrophages in the absence of rIL-18 (P , 0.01; Fig. 4C, D) . This result provides evidence to support that GSK-3 negatively regulates Rae-1 expression. Consistent with our findings in macrophages, specific inhibition of GSK-3 signaling was sufficient to up-regulate Rae-1 expression on DCs (P , 0.05; Fig.  4E, F) . Taken together, these results suggest that GSK-3 is a negative regulator of Rae-1 expression in accessary cells.
GSK-3 inhibition can partially rescue defective NK-cell activation to VV in IL-18R-deficient mice in vivo
In IL-18R 2/2 mice, NK cells fail to efficiently activate against VV infection [14] . In earlier work, we demonstrated that NK cellextrinsic IL-18 signaling is essential for NK cell activation to VV infection by controlling the expression of Rae-1 [14] . Having shown a critical role for GSK-3 in regulating IL-18-dependent Rae-1 up-regulation, we asked whether suppression of GSK-3 promotes Rae-1 expression and NK-cell activation in vivo. Specifically, we tested whether GSK-3 inhibition restores Rae-1 expression on DCs, the accessory cells necessary in vivo for NKcell activation to VV. Furthermore, we asked whether GSK-3 inhibition could rescue NK-cell activation to VV in IL-18R
mice. For this in vivo rescue experiment, we chose to focus on DCs, given that they have a better defined in vivo role in NK cell activation, particularly in the context of VV infection. To test this possibility, WT and IL-18R 2/2 mice were given the specific GSK-3 inhibitor SB216763 or vehicle control intraperitoneally, followed by infection with VV 1 day later. Twenty-four hours after infection, the mice were analyzed for Rae-1 expression on DCs and NK-cell activation. We observed that in vivo administration of the GSK-3 inhibitor promoted Rae-1 expression on DCs (P , 0.05) in infected IL-18R 2/2 mice compared with untreated control (Fig. 5) . This rescue was partial, however, as it did not fully restore Rae-1 expression on IL-18R 2/2 DCs to the level of that in their WT counterparts. The expression of Rae-1 on naive WT DCs was not increased by GSK-3 inhibitor treatment alone, suggesting the importance of other multiple pathways to induce Rae-1 upregulation in vivo. Furthermore, in vivo GSK-3 inhibition could partially restore NK-cell activation in IL-18R 2/2 mice as measured by intracellular staining for IFN-g (P , 0.0001; Fig. 6A , B) and GRB (P , 0.0001; Fig. 6C, D) production, leading to a better viral control (Fig. 7) . These results support that in vivo GSK-3 inhibition can promote Rae-1 expression on DCs and partially rescue 
DISCUSSION
In this report, we investigated the mechanism underlying IL-18-dependent up-regulation of the NKG2D ligand, Rae-1, in accessory cells for NK-cell activation. We found that IL-18-mediated Rae-1 up-regulation is dependent on the MyD88-PI3K pathway. We further demonstrated that IL-18 signaling through PI3K led to the inhibitory phosphorylation of GSK-3 and that GSK-3 is a negative regulator of Rae-1. Finally, we demonstrated that in vivo inhibition of GSK-3 could restore Rae-1 up-regulation on IL18R 2/2 DCs to partially rescue NK-cell activation against VV, leading to a better viral control in IL-18R 2/2 mice.
Our observation that IL-18 signals through PI3K to up-regulate Rae-1 expression is consistent with the role for PI3K signaling in NKG2D ligand expression in cancer cell lines and during MCMV infection [19] . Exactly how PI3K signaling contributed to NKG2D ligand expression, however, was not clear from this previous work. In this study, we found one mechanism by which PI3K may influence Rae-1 expression through its inhibition of GSK-3. However, PI3K may control Rae-1 expression through multiple signaling pathways. The PI3K-Akt-GSK-3 pathway, though necessary, may not be the only one. Indeed the absence of an increase in Rae-1 expression on DCs in WT naive mice treated with GSK-3 inhibitor suggests that other pathways are also important in vivo. Nevertheless, we hope that the identification of this novel cell signaling pathway in Rae-1 regulation will broaden possible immunotherapies designed to harness NKG2D-mediated killing.
How GSK-3 controls the expression of Rae-1 remains to be defined. Two particular reports seemed relevant to our investigation. In one, E2F transcription factors were found to be able to directly transcribe Rae-1 in proliferating fibroblasts [26] . In another, the translation initiation complex was identified as playing a crucial role in Rae-1 translation, given the mRNA's long 59-untranslated region, during oncogenic Ras-mediated Rae-1 upregulation [27] . Both E2F and the translation initiation complex are negatively regulated by GSK-3 [22] [23] [24] [25] . Based on these observations, we speculate that GSK-3 could regulate Rae-1 expression in accessory cells by its inhibition of these molecules important to Rae-1 transcription and translation. In addition, GSK-3 could also regulate the half-life of Rae-1 mRNA. Furthermore, a recent report showed that GSK-3 inhibition upregulates MICA expression on human multiple myeloma cell lines; correlated this finding with down-regulation of STAT3, a negative regulator of MICA transcription; and found that constitutively active STAT3 could prevent MICA up-regulation in the face of GSK-3 inhibition [28] . This alternative mechanism may prove true beyond these human cancer cell lines, though it may not apply to Rae-1 expression on murine accessory cells. Finally, we tested the functional relevance of our in vitro mechanistic work by asking whether in vivo GSK-3 inhibition could up-regulate Rae-1 expression on DCs and rescue NK-cell activation in response to VV in IL-18R 2/2 mice. Upon GSK-3 inhibitor treatment, we found that Rae-1 expression increases on DCs in IL-18R 2/2 mice with concomitant increases in NK cell production of IFN-g and GRB, resulting in improved viral control. The data suggest physiologic relevance for our model of IL-18 control of Rae-1 expression through inhibition of GSK-3. They show the correlation of the Rae-1 up-regulation achieved through GSK-3 inhibition with increases in NK-cell activation. However, the data remain correlative and complicated by any direct effects GSK-3 inhibition may have on NK cells. Furthermore, a full rescue of NKcell activation in IL-18R 2/2 mice cannot be achieved, because IL-18 likely also acts directly on NK cells in a fashion that does not depend on NKG2D or GSK-3 signaling.
In conclusion, we have revealed that IL-18R signaling promotes Rae-1 expression through the MyD88-PI3K-GSK3 pathway in accessory cells and that GSK-3 inhibition in vivo appears capable of up-regulating Rae-1 expression on DCs and partially rescuing defective NK-cell activation against VV, leading to a better viral control in IL-18R 
